Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Bombay-Stock-Exchange"

4 News Found

Remedium unveils Rights Issue post Rs. 182.7 crore UK deal to drive global expansion
News | April 24, 2025

Remedium unveils Rights Issue post Rs. 182.7 crore UK deal to drive global expansion

The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience

Borosil Scientific debuts on stock exchange
News | June 08, 2024

Borosil Scientific debuts on stock exchange

This strategic decision will unlock significant value for our scientific and industrial products business

Cabinet approves foreign investment of up to Rs. 9,589 crore in Suven Pharmaceuticals
Policy | September 14, 2023

Cabinet approves foreign investment of up to Rs. 9,589 crore in Suven Pharmaceuticals

The approval is for acquisition of up to 76.1% equity shares of Suven Pharmaceuticals by Berhyanda Limited

Piramal Pharma strengthens board by inducting three new board members
People | July 11, 2022

Piramal Pharma strengthens board by inducting three new board members

The appointments will add to the well-diversified experience that currently exists on the PPL board.

Latest Stories

Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr

Sigachi Industries signs MoU with Respilon Group

USFDA inspects Marksans’s subsidiary Time-Cap Laboratories' manufacturing facility

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging